News Quantified

PASG – passage bio, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Passage Bio (NASDAQ:PASG) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.

Passage Bio (NASDAQ:PASG) had its price target raised by analysts at Chardan Capital from $6.00 to $21.00. They now have a "buy" rating on the stock.

Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights [Yahoo! Finance]

Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights

Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference

14.9%

BEAT

1.2%

BEAT

-8.6%

MISS

-12.3%

BEAT

Chardan Capital

Form SCHEDULE 13G/A Passage BIO, Inc. Filed by: Lynx1 Capital Management LP

Form 10-Q Passage BIO, Inc. For: Sep 30

Form 8-K Passage BIO, Inc. For: Nov 10

Form 8-K Passage BIO, Inc. For: Sep 16

Form 4 Passage BIO, Inc. For: Sep 11 Filed by: Nichols Weston

Top News Gainers

3/27 Form 8-K Passage BIO, Inc. For: Mar 26 25.5%

3/24 Passage Bio (NASDAQ: PASG) is now covered by analysts at Goldman Sachs Group Inc. They set a "buy" rating on the stock. 12.2%

4/10 Passage Bio (NASDAQ: PASG) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $18.00 price target on the stock. 10.1%

5/1 Passage Bio (NASDAQ: PASG) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $21.00 price target on the stock. 8.1%

3/25 Passage Bio (NASDAQ: PASG) is now covered by analysts at Chardan Capital. They set a "buy" rating on the stock. 5.1%

3/9 Passage Bio Announces Exercise of Underwriters’ Option to Purchase Additional Shares 4.6%

2/28 Passage Bio shares soar 19% in their trading debut despite massive market selloff [MarketWatch] 3.3%

3/3 Form 4 Passage BIO, Inc. For: Mar 03 Filed by: Cale Edgar B. 3.0%

3/5 Bankers try to keep IPO party going amid coronavirus market jitters [Reuters] 2.3%

4/14 Form 8-K Passage BIO, Inc. For: Apr 10 2.1%

Top News Decliners

3/15 Coronavirus and market volatility shuts down the IPO market for potential listings like Airbnb [CNBC] -33.8%

3/25 Form 4 Passage BIO, Inc. For: Mar 24 Filed by: Countouriotis Athena -19.8%

3/6 Form SC 13G Passage BIO, Inc. Filed by: Vivo Capital VIII, LLC -9.4%

3/26 Form SEC STAFF LETTER Passage BIO, Inc. -8.1%

4/21 FDA Grants Passage Bio Orphan Drug Designation for PBGM01 for Treatment of Infantile GM1 Gangliosidosis -7.4%

3/12 Form 3/A Passage BIO, Inc. For: Feb 27 Filed by: Ratcliffe Liam -7.1%

3/2 Form 4 Passage BIO, Inc. For: Feb 27 Filed by: SQUINTO STEPHEN P -7.0%

3/12 Form SC 13G Passage BIO, Inc. Filed by: Access Industries Holdings LLC -6.7%

4/23 Passage Bio (NASDAQ: PASG) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.1%

4/3 Form 8-K Passage BIO, Inc. For: Apr 03 -3.9%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day